Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital

Key Points

• D. Boral Capital initiated coverage on Prelude Therapeutics with a "buy" rating and a $9.00 price target, implying roughly a 91.5% upside from the stock's then-current price.
• Large insider purchases were disclosed: Director David P. Bonita and OrbiMed Advisors each bought about 2,815,315 shares at $4.44 (≈$12.5M each), and insiders now own roughly 63.9% of the company.
• MarketBeat shows a consensus rating of "Hold" with a $7.67 consensus price target; the stock traded around $4.70 (market cap ≈ $296M) and last quarter reported EPS of -$0.20 (beat) while revenue of $5.64M missed estimates.

Analysts at D. Boral Capital initiated coverage on shares of Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) in a research note issued on Monday. The firm set a "buy" rating and a $9.00 price target on the stock. D. Boral Capital's price objective suggests a potential upside of 91.49% from the company's current price.

Other research analysts have also recently issued reports about the stock. Zacks Research raised shares of Prelude Therapeutics to a "hold" rating in a report on Tuesday, April 28th. Citizens Jmp lifted their target price on shares of Prelude Therapeutics from $3.00 to $6.00 and gave the stock a "market outperform" rating in a report on Wednesday, March 11th. Weiss Ratings raised shares of Prelude Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday. HC Wainwright lifted their target price on shares of Prelude Therapeutics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, April 27th. Finally, Wall Street Zen cut shares of Prelude Therapeutics from a "buy" rating to a "hold" rating in a report on Sunday, January 18th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Prelude Therapeutics has a consensus rating of "Hold" and a consensus price target of $7.67.

Prelude Therapeutics Stock Performance

NASDAQ:PRLD opened at $4.70 on Monday. The company has a 50-day moving average price of $3.65 and a 200-day moving average price of $2.54. Prelude Therapeutics has a 12 month low of $0.73 and a 12 month high of $5.54. The stock has a market cap of $296.10 million, a price-to-earnings ratio of -3.64 and a beta of 1.11.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last posted its earnings results on Tuesday, March 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.13. The company had revenue of $5.64 million during the quarter, compared to analysts' expectations of $20.50 million. Equities analysts forecast that Prelude Therapeutics will post -0.93 EPS for the current fiscal year.

Insider Activity at Prelude Therapeutics

In other Prelude Therapeutics news, Director David P. Bonita bought 2,815,315 shares of the business's stock in a transaction that occurred on Tuesday, April 21st. The stock was bought at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following the completion of the transaction, the director owned 11,808,945 shares of the company's stock, valued at $52,431,715.80. This represents a 31.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc bought 2,815,315 shares of the business's stock in a transaction that occurred on Tuesday, April 21st. The shares were acquired at an average price of $4.44 per share, with a total value of $12,499,998.60. Following the completion of the transaction, the director directly owned 11,808,945 shares of the company's stock, valued at $52,431,715.80. This trade represents a 31.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 63.90% of the company's stock.

Institutional Trading of Prelude Therapeutics

Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its position in Prelude Therapeutics by 170.7% during the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company's stock valued at $26,000 after buying an additional 21,330 shares during the period. Marshall Wace LLP bought a new stake in Prelude Therapeutics during the second quarter valued at approximately $34,000. XTX Topco Ltd grew its position in Prelude Therapeutics by 72.4% during the second quarter. XTX Topco Ltd now owns 42,573 shares of the company's stock valued at $34,000 after buying an additional 17,873 shares during the period. Shay Capital LLC bought a new position in shares of Prelude Therapeutics in the second quarter worth approximately $61,000. Finally, Jane Street Group LLC bought a new position in shares of Prelude Therapeutics in the second quarter worth approximately $74,000. 79.72% of the stock is currently owned by institutional investors.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude's pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude's lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.